J&J signs deal with Chinese company for hepatitis B drug
(Reuters) - Johnson & Johnson on Thursday said it licensed rights from a Chinese drugmaker to drugs that spur the immune system to help fight diseases, which it hopes will become a key part of a cure for chronic hepatitis B.
Aucun commentaire:
Enregistrer un commentaire